Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW. Rebeiz AG, et al. Among authors: califf rm. Am J Cardiol. 2005 Mar 1;95(5):611-4. doi: 10.1016/j.amjcard.2004.10.038. Am J Cardiol. 2005. PMID: 15721101
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Cho L, et al. J Am Coll Cardiol. 2000 Aug;36(2):381-6. doi: 10.1016/s0735-1097(00)00746-4. J Am Coll Cardiol. 2000. PMID: 10933346 Free article.
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Lincoff AM, et al. Among authors: califf rm. Am J Cardiol. 1997 Feb 1;79(3):286-91. doi: 10.1016/s0002-9149(96)00749-7. Am J Cardiol. 1997. PMID: 9036746 Clinical Trial.
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Mandak JS, et al. Among authors: califf rm. J Am Coll Cardiol. 1998 Jun;31(7):1518-24. doi: 10.1016/s0735-1097(98)00130-2. J Am Coll Cardiol. 1998. PMID: 9626829 Free article. Clinical Trial.
1,332 results